市場調查報告書

乾眼症疾病市場 - 成長,趨勢,及預測(2019年 - 2024年)

Dry Eye Disease Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 892622
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
乾眼症疾病市場 - 成長,趨勢,及預測(2019年 - 2024年) Dry Eye Disease Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 115 Pages
簡介

全球乾眼症疾病市場在2018年估算為45億3,922萬美金。該市場在2019年∼2024年間,預測將以5.23%的年複合成長率成長,2024年達到61億7,596萬美元。

本報告提供全球乾眼症疾病市場的相關調查,市場趨勢和機會,成長及阻礙因素,產品、流通管道、各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查的成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各產品
    • 人工淚液
    • 抗發炎藥
    • 淚點塞
    • 分泌促進物質
    • 其他
  • 各流通管道
    • 醫院藥局
    • 獨立型藥局及藥妝店
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Allergan PLC
    • Novartis AG
    • 參天製藥株式會社
    • OASIS Medical
    • Bausch Health
    • Sun Pharmaceutical Industries Ltd
    • 大塚製藥株式會社
    • Johnson & Johnson
    • VISUfarma
    • Sentiss Pharma Pvt. Ltd

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64754

The Dry Eye Disease Market is expected to register a CAGR of 5.8% during the forecast period. Several factors, such as aging, decrease in the supportive hormones, systemic inflammatory diseases, ocular surface diseases, or surgeries that affect the cholinergic nerves, which stimulate tear secretion, may be associated with the rise in dry eye-related diseases.

  • A significant percentage of the global population (middle age to older age) suffers from the dry eye disease. The disease is particularly more common among women than in men.
  • According to the World Ageing 2019 report, estimates that there were about 703 million population aged 65 years or over in the world in 2019. This number is projected to double to 1.5 billion in 2050. Moreover, by 2050, 1 in 6 people in the world will be over the age of 65, up from 1 in 11 in 2019. As number of elderly population are projected to increase and this population are more prone to eye related disorders such as dry eye which ultimately drives the market in near future.
  • Additionally, exposure to computer screens for long hours and long-term usage of contact lens may cause dry eye disease.
  • Several manufacturers are exploring the alternative drug class or procedure, with improvement in diagnostic tools, to identify and enhance the tear stimulating factors.
  • Thus, the rise in geriatric population, technological advancements, and upcoming products are expected to help in the growth of the market.

Key Market Trends

Corticosteroid Drugs Segment is Expected to Hold a Major Market Share in the Dry Eye Disease Market

Corticosteroids are effective anti-inflammatory drugs. These are widely available and rapidly relieve the symptoms and signs of moderate and severe dry eye diseases. These drugs are highly useful in short-term efficacy, and thus, are prescribed mostly for acute cases of dry eye diseases. However, the long-term usage of these drugs has major side effects, such as intraocular pressure elevation and cataract progression. Two of the major companies established in this segment are Bausch Health and AbbVie Inc (Allergan Plc). Often, these companies, as well as doctors, recommend corticosteroid, along with antibiotic therapy.

According to the World Population Ageing 2019 report, in Italy population aged 65 years or over in 2019 was 13.93 million (23%) and this number is projected to reach to 16.46 million (27.9%) in 2030. As the number of the elderly population is expected to grow in coming years who are more prone to eye-related disorders which ultimately drives the market in future.

Some of the common interventions include dietary omega-3 essential fatty acids, such as fish oils or flaxseed oil, or the use of lipid-based artificial tears to augment the deficient lipid layer, and/or a short course of a topical ester-based corticosteroid, in order to address the inflammatory component of the dry eye. Overall, this segment has the largest share under anti-inflammatory drugs in the market studied, and is expected to register a steady CAGR over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

Geographically, North American holds a major share. As per Government of Canada Statistics report 2019, in 2019 Canadian older population included 6,592,611 which accounted for 17.5% of the Canadian population. Although the proportion of seniors in Canada has been increasing over time. Moreover, aging of Canada's population was influenced by the baby boomers who turned 65 in the last five years as well as increasing life expectancy. As number of older population is expected to grow in near future this population are more prone to eye related diseases which shows positive impact on market. Thus, North America dominates with major share in near future. Whereas the Asia-Pacific region is estimated to be the fastest growing. Several factors, such as hospital infrastructure, procurement of new technology devices for the diagnoses of diseases, early market approvals of the product, large number of ophthalmic surgeries, and awareness in the society, drive the market in North American. Meanwhile, in Asia-Pacific, the large number of generic production, good distribution of local and international players, and the fast economic growth of the countries are the factors driving the growth of the market.

Competitive Landscape

The Dry Eye Disease Market is moderately competitive. In terms of market share, a few of the major players currently dominate the market. With the rising geriatric population and high prevalence of diseases, few other smaller players are expected to enter the market in the coming years. Some of the major players in the market are AbbVie Inc (Allergan Plc), Alcon Inc, Santen Pharmaceutical Co. Ltd, OASIS Medical, and Bausch Health Companies Inc, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Dry Eye Disease
    • 4.2.2 Emergence of Novel Diagnostic Tools
    • 4.2.3 Technological Advancements and Promising Pipeline Products
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Specialty Dry Eye Products with Complex Reimbursement Scenario
    • 4.3.2 Availability of Alternative Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Artificial Tears
    • 5.1.2 Anti-inflammatory Drugs
      • 5.1.2.1 Cyclosporine
      • 5.1.2.2 Corticosteroid
      • 5.1.2.3 Other Anti-inflammatory Drugs
    • 5.1.3 Punctal Plugs
    • 5.1.4 Secretagogues
    • 5.1.5 Other Products
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Independent Pharmacies and Drug Stores
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc (Allergan Plc)
    • 6.1.2 Alcon Inc
    • 6.1.3 Santen Pharmaceutical Co. Ltd
    • 6.1.4 OASIS Medical
    • 6.1.5 Bausch Health Companies Inc
    • 6.1.6 Sun Pharmaceutical Industries Ltd
    • 6.1.7 Otsuka Pharmaceutical Co. Ltd
    • 6.1.8 Johnson & Johnson
    • 6.1.9 VISUfarma
    • 6.1.10 Sentiss Pharma Pvt Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS